Martha Brumfield on the Success and Continued Growth of CPTR

How CPTR has grown into a vital and innovative catalyst in the fight against TB



US NIAID’s Anthony Fauci on Halting Drug Resistance

New TB drug regimens and diagnostics are needed to fight TB and MDR-TB


EMA’s Hans-Georg Eichler on Innovation Within Regulation

Instead of gatekeepers, regulators must act as enablers of innovation


Advocate Mayowa Joel on Community Engagement

Effective and sustainable community engagement programs is a critical priority



Host for new TB clinical trial data-sharing platform selected

TUCSON, Ariz., April 29, 2015 — The non-profit Critical Path Institute has been selected to host a new tuberculosis (TB) clinical trial data sharing platform. The initiative will start by creating a common database from three Phase III clinical trials earlier supported by the Special Programme for Research and Training in Tropical Diseases (TDR), the […]

May 4, 2015 Drug Development Press Releases clinical trials

World TB Day 2015 Supplement Profiles TB Diagnostic Landscape

Read the supplement to the Journal of Infectious Diseases called “Tuberculosis Diagnostics in 2015: Landscape, Priorities, Needs, and Prospects,” which can be found here. Madhukar Pai and Marco Schito write: “In 2015, tuberculosis remains a major global health problem, and drug-resistant tuberculosis is a growing threat. Although tuberculosis diagnosis in many countries is still reliant on older tools, […]

March 20, 2015 Drug Development RDST

From the Working Groups

Clinical Trials Infrastructure Workgroup Q1 2015 Update

The Clinical Trials Infrastructure Workgroup (CTI-WG) identifies efficiencies across clinical trial sites and supports a coordinated approach to clinical research for TB regimen development. Progress over the first quarter of 2015 can be read here.

March 16, 2015

Global Regulatory Pathways Workgroup Q1-2015 Update

The Global Regulatory Pathways Workgroup (GRP-WG) identifies efficiencies in the regulatory pathway to develop a novel regimen by fostering dialogue among key regulatory agencies, WHO, and NTPs. The Workgroup works to develop of pathway for regulatory approval that incentivizes regimens development. Regulators from countries or regions with high TB burden are included in this process.

March 16, 2015

Stakeholder & Community Engagement Workgroup Q1-2015 Update

The Stakeholder and Community Engagement Workgroup (SCE-WG) facilitates the development of regimens by early, effective, and appropriate collaboration of key stakeholders and by building awareness and support among communities. The ability to successfully engage the community while conducting clinical trials is an essential component for regimen development.

March 16, 2015
About CPTR

Through partnership, CPTR speeds the development of new and markedly improved drug regimens for tuberculosis.